Search results
Results from the WOW.Com Content Network
David J. Acer (November 11, 1949 – September 3, 1990) was an American dentist who allegedly infected six of his patients, including Kimberly Bergalis, with HIV. [1] The Acer case is considered the first documented HIV transmission from a healthcare worker to a patient in the United States, [2] though the means of transmission remain unknown. [3]
Kimberly Ann Bergalis (January 19, 1968 – December 8, 1991) was an American woman who was one of six patients purportedly infected with HIV by dentist David J. Acer, who was infected with HIV and died of AIDS on September 3, 1990. [1]
Photosensitivity with HIV infection is a skin condition resembling polymorphous light eruption, actinic prurigo, or chronic actinic dermatitis, seen in about 5% of HIV-infected people. [ 1 ] : 38
People who received the tainted Botox developed symptoms of botulism, including difficulty breathing or swallowing, blurred or double vision, slurred speech and drooping eyelids. At least 11 have ...
HIV-associated pruritus is a cutaneous condition, an itchiness of the skin, that occurs in up to 30% of HIV infected people, occurs when the T-cell count drops below 400 per cubic mm. [1]: 417 See also
Infection with HIV is determined by an HIV test.As of 2021, 85% of all people living with HIV knew their status. [2]The Joint United Nations Program on HIV/AIDS (UNAIDS), Amnesty International, the Global Network of Sex Work Projects and the Global Network of People Living with HIV/AIDS, have all condemned forced HIV testing actions as infringements on human rights and conflicting with proven ...
Since the beginning of the epidemic, 84.2 million [64.0–113.0 million] people have been infected with the HIV virus and about 40.1 million [33.6–48.6 million] people have died of HIV. Globally, 38.4 million [33.9–43.8 million] people were living with HIV at the end of 2021.
helped to define international guidelines for the treatment of primary HIV infection and associated opportunistic infections and prophylactic regimens for these secondary infections, identified biological markers, such as CD4+ counts and viral load for predicting a drug's effectiveness and disease progression, and